Rhodopsin

First healthy volunteer dosed with OCT980.

Octant has begun the first in-human clinical testing of OCT980, an investigational oral therapy designed to slow or halt the progression of rhodopsin-associated autosomal dominant retinitis pigmentosa.

caused by certain RHO gene mutations that lead to protein misfolding.

Protein misfolding is when proteins fail to fold into their correct functional three-dimensional shapes.

Instead of performing their normal jobs, these abnormally shaped proteins become insoluble and sticky.

They clump together into toxic aggregates which can disrupt cellular functions and cause various degenerative diseases.

RHO-ADRP is the most common form of autosomal dominant RP.

It is one of the most severe forms of the condition with more than 150 known RHO mutations.